IGC Pharma, Inc.IGCNYSE
Loading
Year-over-year research & development expense growth
Percentile
P90
Near historical high
vs 2Y Ago
1.2x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 86.60% |
| Q2 2025 | -14.64% |
| Q1 2025 | 17.02% |
| Q4 2024 | -7.09% |
| Q3 2024 | 3.15% |
| Q2 2024 | 3.98% |
| Q1 2024 | -5.32% |
| Q4 2023 | -28.79% |
| Q3 2023 | 69.75% |
| Q2 2023 | 51.52% |
| Q1 2023 | -38.83% |
| Q4 2022 | 4.95% |
| Q3 2022 | -44.91% |
| Q2 2022 | 13.06% |
| Q1 2022 | 227.06% |
| Q4 2021 | 36.59% |
| Q3 2021 | -37.84% |
| Q2 2021 | 32.93% |
| Q1 2021 | 116.88% |
| Q4 2020 | -29.68% |
| Q3 2020 | -1.35% |
| Q2 2020 | -10.12% |
| Q1 2020 | -16.27% |
| Q4 2019 | 32.88% |
| Q3 2019 | -10.12% |
| Q2 2019 | -69.54% |
| Q1 2019 | 388.55% |
| Q4 2018 | -40.29% |
| Q3 2018 | 672.22% |
| Q2 2018 | -73.72% |
| Q1 2018 | 0.00% |
| Q4 2017 | -100.00% |
| Q3 2017 | 37.96% |
| Q2 2017 | -50.41% |
| Q1 2017 | 0.00% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |
| Q2 2016 | 0.00% |
| Q1 2016 | 0.00% |
| Q4 2015 | 0.00% |